with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent Pneumocystis jirovecii pneumonia. | 1099 is less commonly used in younger children receiving rituximab but should be considered. Recommendation: For patients with GPA/MPA in remission and stage 5 chronic kidney disease, we conditionally recommend evaluation for renal transplantation. Outcomes of kidney transplantation in patients with AAV are similar to those in patients receiving transplants for other reasons, with disease relapses in the transplanted kidney being rare Recommendation: For patients with active GPA/MPA who are unable to receive other immunomodulatory therapy, we conditionally recommend administering IVIG. IVIG should not be used routinely to treat GPA/MPA (see above recommendation). However, in the rare instances in which patients with active disease may not be able to receive conventional immunosuppressive therapy (e.g., sepsis or